232 related articles for article (PubMed ID: 23772610)
1. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients.
Tran KD; Wolverton JE; Soter NA
Br J Dermatol; 2013 Oct; 169(4):916-21. PubMed ID: 23772610
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris.
Baum S; Greenberger S; Samuelov L; Solomon M; Lyakhovitsky A; Trau H; Barzilai A
Eur J Dermatol; 2012; 22(1):83-7. PubMed ID: 22266247
[TBL] [Abstract][Full Text] [Related]
3. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975.
Lever WF; Schaumburg-Lever G
Arch Dermatol; 1977 Sep; 113(9):1236-41. PubMed ID: 900969
[TBL] [Abstract][Full Text] [Related]
5. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
Heaphy MR; Albrecht J; Werth VP
Arch Dermatol; 2005 Jun; 141(6):699-702. PubMed ID: 15967915
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
Werth VP
Arch Dermatol; 1996 Dec; 132(12):1435-9. PubMed ID: 8961871
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
[TBL] [Abstract][Full Text] [Related]
9. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin.
Mashkilleyson N; Mashkilleyson AL
Acta Derm Venereol; 1988; 68(5):413-21. PubMed ID: 2461025
[TBL] [Abstract][Full Text] [Related]
10. Oropharyngeal pemphigus vulgaris and clinical remission: a long-term, longitudinal study.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E
Am J Clin Dermatol; 2010; 11(2):137-45. PubMed ID: 20141235
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of pemphigus. Critical remarks based on 44 clinical cases].
Smolle J
Hautarzt; 1985 Feb; 36(2):96-102. PubMed ID: 2985524
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria.
Perez A; Woods A; Grattan CE
Br J Dermatol; 2010 Jan; 162(1):191-4. PubMed ID: 19903174
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)].
Benoit Corven C; Carvalho P; Prost C; Verret JL; Saiag P; Noblesse I; Bedane C; Chosidow O; Young P; Roujeau JC; Joly P
Ann Dermatol Venereol; 2003 Jan; 130(1 Pt 1):13-5. PubMed ID: 12605150
[TBL] [Abstract][Full Text] [Related]
14. Pemphigus vulgaris in a patient with arthritis and uveitis: successful treatment with immunosuppressive therapy and acyclovir.
Pranteda G; Carlesimo M; Bottoni U; Di Napoli A; Muscianese M; Pimpinelli F; Cordiali P; Laganà B; Pranteda G; Di Carlo A
Dermatol Ther; 2014; 27(4):215-8. PubMed ID: 24548566
[TBL] [Abstract][Full Text] [Related]
15. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
Morrison LH
J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
Vyas N; Patel NS; Cohen GF
J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
[TBL] [Abstract][Full Text] [Related]
17. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents.
McCarty M; Fivenson D
J Am Acad Dermatol; 2014 Sep; 71(3):475-9. PubMed ID: 24906610
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
Baskan EB; Yilmaz M; Tunali S; Saricaoglu H
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052
[TBL] [Abstract][Full Text] [Related]
19. High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study.
Chaidemenos G; Apalla Z; Koussidou T; Papagarifallou I; Ioannides D
J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):206-10. PubMed ID: 20569289
[TBL] [Abstract][Full Text] [Related]
20. Assessing the use of methotrexate as an alternate therapy for pemphigus vulgaris and pemphigus foliaceus.
Kolla A; Shah P; Cymerman R; Fruchter R; Adotama P; Soter NA
Dermatol Ther; 2022 Aug; 35(8):e15661. PubMed ID: 35734997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
